The Europe Carrier Screening Market is expected to witness market growth of 12.95% CAGR during the forecast period (2021-2027).
The carrier screening market is expected to witness lucrative growth opportunities due to the rise in importance of early disease detection and prevention, increasing demand for personalized medicine, and rising applications of screening tests in genetic disorders, which is expected to open new growth avenues for the overall carrier screening market during the forecast period.
The increasing popularity of smart healthcare procedures is driving the growth of the carrier screening market. In addition, the growing cases of many genetic diseases and other diseases that occur due to the errors in genetic codes in various nations of this region will also contribute to the increasing demand for carrier screening in the region. The population across this region is more aware of maintaining a healthy lifestyle along with getting a regular checkup, for which they are highly adopting procedures that can detect the abnormalities in their genes in order to prevent themselves from any disease in the future.
Due to carrier screening procedures, the individuals get to know about the defects in their genetic codes, thereby creating awareness regarding different diseases related to genes. All such factors are collaboratively working to boost the demand and growth for the carrier screening market in the regional market.
Based on Technology, the market is segmented into DNA Sequencing, Microarrays, Polymerase Chain Reaction and Other technology. Based on End user, the market is segmented into Hospital and Clinics, Physician Offices, Reference Laboratories and Other End Users. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The End-user segment is likely to showcase a similar kind of trend even during the forecast period. Factors such as the growing occurrence of genetic disorders and developments in carrier screening are likely to propel the growth of this segment.
The Germany market dominated the Europe Carrier Screening Market by Country in 2020, and is expected to continue to be a dominant market till 2027; thereby, achieving a market value of $149.2 million by 2027. The UK market is is expected to experience a CAGR of 9.9% during (2021 - 2027). Additionally, The France market is exhibiting a CAGR of 12.4% during (2021 - 2027).
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Quest Diagnostics, Incorporated, Thermo Fisher Scientific, Illumina, Inc., Eurofins Scientific Group, Invitae Corporation, OPKO Health, Inc., Fulgent Genetics, Sema4 OpCo, Inc., Myriad Genetics, Inc., and Natera, Inc.
Scope of the Study
Market Segments Covered in the Report:
By Type
- Expanded Carrier Screening and
- Targeted Disease Carrier Screening
By Technology
- DNA Sequencing
- Microarrays
- Polymerase Chain Reaction and
- Other technology
By End User
- Hospital and Clinics
- Physician Offices
- Reference Laboratories and
- Other End Users
By Country
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Key Market Players
List of Companies Profiled in the Report:
- Quest Diagnostics, Incorporated
- Thermo Fisher Scientific
- Illumina, Inc.
- Eurofins Scientific Group
- Invitae Corporation
- OPKO Health, Inc.
- Fulgent Genetics
- Sema4 OpCo, Inc.
- Myriad Genetics, Inc.
- Natera, Inc.
Unique Offerings from the Publisher
- Exhaustive coverage
- The highest number of market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Companies Mentioned
- Quest Diagnostics, Incorporated
- Thermo Fisher Scientific
- Illumina, Inc.
- Eurofins Scientific Group
- Invitae Corporation
- OPKO Health, Inc.
- Fulgent Genetics
- Sema4 OpCo, Inc.
- Myriad Genetics, Inc.
- Natera, Inc.
Methodology
LOADING...
